Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival : TBCRC 005 Prospective Trial
©2022 American Association for Cancer Research..
PURPOSE: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay using the GeneXpert cartridge system for early assessment of disease progression in MBC.
EXPERIMENTAL DESIGN: The 9-marker LBx-BCM prototype assay was evaluated in TBCRC 005, a prospective biomarker study, using plasma collected at baseline, week 4, and week 8 from 144 patients with MBC.
RESULTS: At week 4, patients with MBC with high cumulative methylation (CM) had a significantly shorter median PFS (2.88 months vs. 6.60 months, P = 0.001) and OS (14.52 months vs. 22.44 months, P = 0.005) compared with those with low CM. In a multivariable model, high versus low CM was also associated with shorter PFS (HR, 1.90; 95% CI, 1.20-3.01; P = 0.006). Change in CM from baseline to week 4 (OR, 4.60; 95% CI, 1.77-11.93; P = 0.002) and high levels of CM at week 4 (OR, 2.78; 95% CI, 1.29-5.99; P = 0.009) were associated with progressive disease at the time of first restaging. A robust risk model based on week 4 circulating CM levels was developed to predict disease progression as early as 3 months after initiating a new treatment.
CONCLUSIONS: The automated LBx-BCM prototype assay is a promising clinical tool for detecting disease progression a month after initiating treatment in women with MBC undergoing routine care. The next step is to validate its clinical utility for specific treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 29(2023), 4 vom: 16. Feb., Seite 784-790 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Visvanathan, Kala [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 22.02.2023 Date Revised 23.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/1078-0432.CCR-22-2128 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350463336 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350463336 | ||
| 003 | DE-627 | ||
| 005 | 20231226045047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-22-2128 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350463336 | ||
| 035 | |a (NLM)36534524 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Visvanathan, Kala |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival |b TBCRC 005 Prospective Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2023 | ||
| 500 | |a Date Revised 23.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2022 American Association for Cancer Research. | ||
| 520 | |a PURPOSE: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay using the GeneXpert cartridge system for early assessment of disease progression in MBC | ||
| 520 | |a EXPERIMENTAL DESIGN: The 9-marker LBx-BCM prototype assay was evaluated in TBCRC 005, a prospective biomarker study, using plasma collected at baseline, week 4, and week 8 from 144 patients with MBC | ||
| 520 | |a RESULTS: At week 4, patients with MBC with high cumulative methylation (CM) had a significantly shorter median PFS (2.88 months vs. 6.60 months, P = 0.001) and OS (14.52 months vs. 22.44 months, P = 0.005) compared with those with low CM. In a multivariable model, high versus low CM was also associated with shorter PFS (HR, 1.90; 95% CI, 1.20-3.01; P = 0.006). Change in CM from baseline to week 4 (OR, 4.60; 95% CI, 1.77-11.93; P = 0.002) and high levels of CM at week 4 (OR, 2.78; 95% CI, 1.29-5.99; P = 0.009) were associated with progressive disease at the time of first restaging. A robust risk model based on week 4 circulating CM levels was developed to predict disease progression as early as 3 months after initiating a new treatment | ||
| 520 | |a CONCLUSIONS: The automated LBx-BCM prototype assay is a promising clinical tool for detecting disease progression a month after initiating treatment in women with MBC undergoing routine care. The next step is to validate its clinical utility for specific treatments | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 700 | 1 | |a Cope, Leslie |e verfasserin |4 aut | |
| 700 | 1 | |a Fackler, Mary Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Considine, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Sokoll, Lori |e verfasserin |4 aut | |
| 700 | 1 | |a Carey, Lisa A |e verfasserin |4 aut | |
| 700 | 1 | |a Forero-Torres, Andres |e verfasserin |4 aut | |
| 700 | 1 | |a Ingle, James N |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Nancy U |e verfasserin |4 aut | |
| 700 | 1 | |a Nanda, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Storniolo, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Tulac, Suzana |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatesan, Neesha |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Natalie C |e verfasserin |4 aut | |
| 700 | 1 | |a Marla, Sudhakar |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Bates, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Umbricht, Christopher B |e verfasserin |4 aut | |
| 700 | 1 | |a Wolff, Antonio C |e verfasserin |4 aut | |
| 700 | 1 | |a Sukumar, Saraswati |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 29(2023), 4 vom: 16. Feb., Seite 784-790 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:4 |g day:16 |g month:02 |g pages:784-790 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-22-2128 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 4 |b 16 |c 02 |h 784-790 | ||